Gastrointestinal stromal tumour

The PBS subsidises imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour.

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with imatinib, ripretinib and sunitinib under the National Health Act 1953, section 85 for patients with gastrointestinal stromal tumour (GIST).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing imatinib, ripretinib and sunitinib.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised imatinib to treat resected primary GIST and high risk of recurrence, or imatinib and ripretinib to treat metastatic or unresectable malignant GIST can be made either:

Applications for initial authority approval to prescribe PBS-subsidised sunitinib to treat metastatic or unresectable malignant GIST can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised ripretinib to treat metastatic or unresectable malignant GIST can be made either:

Continuing PBS-subsidised treatment with imatinib to treat resected primary GIST with high risk of recurrence, or imatinib and sunitinib to treat metastatic or unresectable malignant GIST is Authority Required (Streamlined). You don’t need prior authority approval from us for the listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 23 September 2022